Press Releases

Vancouver, British Columbia--(Newsfile Corp. - May 3, 2024) - Nexus Uranium Corp. (CSE: NEXU) (OTCQB: GIDMF) (FSE: 3H1) (the "Company" or "Nexus") is pleased to announce an increase in the ownership of its Independence gold project in Nevada to 51.11%. The Independence gold project is a joint venture between the Company and Americas Gold Exploration Inc. ("AGEI"), whereby the Company increased its ownership from 51% to 51.11% through the dilution of AGEI for failing to... (continue reading...)

Nanotechnology testing results will be used to continue to move towards large scale commercial production

Oakville, Ontario--(Newsfile Corp. - May 3, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings is pleased to announce that the Company is preparing to conduct real-world testing and assessment of the repelling properties of REPELWRAP" film at Giulietta, an... (continue reading...)

A roundup of the most newsworthy press releases from PR Newswire this week, including Southwest's new Wednesday deals, TIME's list of the most influential people in health and a new Jif® flavor.

NEW YORK, May 3, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some... (continue reading...)

Total Revenue of $128 Million; Protolabs Network Revenue up 39% YoY to $24 Million

GAAP Earnings Per Share of $0.20, Non-GAAP Earnings Per Share of $0.40

MINNEAPOLIS--(BUSINESS WIRE)-- Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the first quarter ended March 31, 2024.

First Quarter 2024 Financial Highlights:

• Revenue was $127.9 million,... (continue reading...)

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒ ‒ Affirming 2024 Full Year Guidance ‒

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) announced its... (continue reading...)